Denmark’s Breye Therapeutics raises €67.5 million to advance oral therapies for early treatment of retinal diseases
Breye Therapeutics has completed a €67.5 million Series A funding round to develop oral therapies for retinal diseases. The round was co-led by Mission BioCapital and Novo Holdings.
EU-Startups Denmark Read story →